Class Action Lawsuit Filed for Sage Therapeutics Investors
The Law Offices of Frank R. Cruz recently announced that they have launched a class action lawsuit for investors of Sage Therapeutics, Inc. (SAGE) who bought or acquired securities between April 12, 2021, and July 23, 2024. This lawsuit seeks to tackle concerns stemming from major drops in Sage's stock price, which are linked to misleading statements made about the company’s drug approvals and clinical trials.
Sage Therapeutics and Its Clinical Developments
Sage Therapeutics has been a leader in creating treatments for mental health issues. The company primarily focuses on developing medications for postpartum depression and major depressive disorder. However, its recent progress has faced considerable setbacks. Notably, the New Drug Application for zuranolone received mixed reviews from the U.S. Food and Drug Administration (FDA), causing a significant decline in share value that negatively impacted many investors.
Impact of FDA Approval and Stock Price Drop
On August 4, 2023, Sage reported that although the FDA approved the application for zuranolone to treat postpartum depression, it did not receive approval for major depressive disorder. This news triggered a remarkable stock price plunge of $19.35, or a staggering 53.6%, with shares closing at $16.75 right after the announcement. Such rapid fluctuations underscore the volatility often seen in biotech stocks, particularly those reliant on regulatory nods and trial outcomes.
Ongoing Trials and Their Results
Things became even more complicated when, on April 17, 2024, Sage announced that a Phase 2 study for SAGE-718, aimed at treating mild cognitive impairment related to Parkinson's disease, failed to meet its main goals. This news led to another decline in share price by $3.06, translating to a 19.6% drop, closing the day at $12.57. Clearly, these ongoing setbacks have shaken investor confidence significantly.
Issues Related to Sage-324 Study
More recently, Sage Therapeutics shared disappointing results from a Phase 2 study of Sage-324, designed for treating essential tremors. Unfortunately, the results were again unfavorable, and the company announced it would not pursue clinical development for this drug. This revelation caused a 20.6% drop in stock price, bringing it down to $10.38. These developments have raised considerable worries about the company’s future pipeline and opportunities.
Allegations in the Class Action Lawsuit
The class action lawsuit alleges that during the class period, executives at Sage Therapeutics misled investors by making false statements and leaving out vital negative information regarding the company’s operations and prospects for future growth. Investors were not adequately informed of the likelihood that zuranolone might not achieve the desired FDA approval for MDD. Moreover, trials for drugs SAGE-718 and SAGE-324 apparently did not deliver the expected results.
Participation and Legal Rights of Investors
Investors who have incurred losses due to the recent events are encouraged to take part in the class action lawsuit. If you bought Sage securities within the specified timeframe, you might be eligible to act as a lead plaintiff. Keep in mind that the deadline for filing is set for October 28, 2024. It is important to seek legal advice to fully understand your rights and options and potentially benefit from this lawsuit.
Contact Information for Further Inquiries
If you’re looking for more information about this lawsuit or want to discuss your rights as an investor, please reach out to Frank R. Cruz at The Law Offices of Frank R. Cruz. The office is located at 2121 Avenue of the Stars, Suite 800, Los Angeles, CA 90067. You can contact them by calling 310-914-5007 or emailing info@frankcruzlaw.com. Prospective participants should make sure to provide their details, including mailing address and shareholding information.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit addresses claims from investors who experienced losses in Sage Therapeutics securities due to misleading statements about drug effectiveness and regulatory approvals.
Who can participate in the class action?
Any investor who purchased Sage shares during the specified class period, which runs from April 12, 2021, to July 23, 2024, is eligible to participate.
What are the allegations against Sage Therapeutics?
The allegations include making materially false statements and withholding significant adverse facts about the company’s business and drug development processes.
When is the deadline to file a lead plaintiff motion?
The deadline for filing a lead plaintiff motion is October 28, 2024.
How can I contact The Law Offices of Frank R. Cruz?
You can reach them at 310-914-5007 or via email at info@frankcruzlaw.com for further questions regarding the lawsuit.
